icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 23rd Conference of the Asian Pacific
Association for the Study of the Liver
6-9 June
2013, Singapore
Back grey_arrow_rt.gif
 
 
 
Low rate of danoprevir resistance with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV G1b-infected treatment-naive and treatment-experienced patients
 
 
  Reported by Jules Levin
APASL 2013 Singapore June 6-10
 
S. Le Pogam,1 L. Li,1 M.T. Navarro,2 J. Zhou,3 A. Voulgari,4 N.S. Shulman,2 K. Klumpp,1 I. Najera1 1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Genentech, South San Francisco, CA, USA; 3Roche Product Development - Asia Pacific, Shanghai, China; 4Roche Products Ltd, Welwyn, UK
 
APASL: High SVR24 rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV genotype (G)1/4-infected treatment-naive patients: the DAUPHINE study - (06/09/13)
 
3 & 4 Oral IFN-Free Roche HCV Regimens Studies, Treatment Naïve or Null Responders: setrobuvir+mericitabine+danoprevir/r+rbv. ANNAPURNA Study http://www.natap.org/2012/HCV/090412_01.htm

APASL1.gif

APASL2.gif

APASL3.gif

APASL4.gif

APASL5.gif

APASL6.gif

APASL7.gif

APASL8.gif

APASL9.gif

APASL10.gif